ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset

ANI Pharmaceuticals' growth pivots to Cortrophin Gel as retina headwinds weigh on 2025, with 2026 recovery hopes hinging on specialty momentum and portfolio reset.